Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Interest Coverage 0.95
RDNT's Interest Coverage is ranked lower than
55% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 94.07 vs. RDNT: 0.95 )
RDNT' s 10-Year Interest Coverage Range
Min: 0.22   Max: 1.33
Current: 0.95

0.22
1.33
F-Score: 5
Z-Score: 1.25
M-Score: -3.26
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 7.34
RDNT's Operating margin (%) is ranked higher than
81% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. RDNT: 7.34 )
RDNT' s 10-Year Operating margin (%) Range
Min: -116.39   Max: 16.68
Current: 7.34

-116.39
16.68
Net-margin (%) -0.22
RDNT's Net-margin (%) is ranked higher than
73% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. RDNT: -0.22 )
RDNT' s 10-Year Net-margin (%) Range
Min: -135.47   Max: 13.48
Current: -0.22

-135.47
13.48
ROA (%) -0.22
RDNT's ROA (%) is ranked higher than
74% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. RDNT: -0.22 )
RDNT' s 10-Year ROA (%) Range
Min: -39.36   Max: 13.24
Current: -0.22

-39.36
13.24
ROC (Joel Greenblatt) (%) 17.54
RDNT's ROC (Joel Greenblatt) (%) is ranked higher than
81% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. RDNT: 17.54 )
RDNT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -44.17   Max: 31.78
Current: 17.54

-44.17
31.78
Revenue Growth (3Y)(%) 7.90
RDNT's Revenue Growth (3Y)(%) is ranked higher than
80% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. RDNT: 7.90 )
RDNT' s 10-Year Revenue Growth (3Y)(%) Range
Min: 1.1   Max: 25.5
Current: 7.9

1.1
25.5
EBITDA Growth (3Y)(%) 6.20
RDNT's EBITDA Growth (3Y)(%) is ranked higher than
79% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. RDNT: 6.20 )
RDNT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -43.1   Max: 169.2
Current: 6.2

-43.1
169.2
» RDNT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

RDNT Guru Trades in Q4 2013

Jim Simons 51,500 sh (+241.81%)
» More
Q1 2014

RDNT Guru Trades in Q1 2014

Jim Simons Sold Out
» More
Q2 2014

RDNT Guru Trades in Q2 2014

Jim Simons 798,900 sh (New)
Paul Tudor Jones 10,084 sh (New)
» More
Q3 2014

RDNT Guru Trades in Q3 2014

Paul Tudor Jones Sold Out
Jim Simons 532,800 sh (-33.31%)
» More
» Details

Insider Trades

Latest Guru Trades with RDNT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 961.00
RDNT's P/B is ranked higher than
55% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.49 vs. RDNT: 961.00 )
RDNT' s 10-Year P/B Range
Min: 35.71   Max: 961
Current: 961

35.71
961
P/S 0.56
RDNT's P/S is ranked higher than
96% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.14 vs. RDNT: 0.56 )
RDNT' s 10-Year P/S Range
Min: 0.07   Max: 1.07
Current: 0.56

0.07
1.07
PFCF 120.13
RDNT's PFCF is ranked higher than
80% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. RDNT: 120.13 )
RDNT' s 10-Year PFCF Range
Min: 0.53   Max: 209.67
Current: 120.13

0.53
209.67
EV-to-EBIT 19.57
RDNT's EV-to-EBIT is ranked higher than
87% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. RDNT: 19.57 )
RDNT' s 10-Year EV-to-EBIT Range
Min: 11.4   Max: 37.2
Current: 19.57

11.4
37.2
Shiller P/E 47.13
RDNT's Shiller P/E is ranked higher than
89% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. RDNT: 47.13 )
RDNT' s 10-Year Shiller P/E Range
Min: 8.88   Max: 51.5
Current: 47.13

8.88
51.5
Current Ratio 1.50
RDNT's Current Ratio is ranked higher than
58% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. RDNT: 1.50 )
RDNT' s 10-Year Current Ratio Range
Min: 0.15   Max: 1.72
Current: 1.5

0.15
1.72
Quick Ratio 1.50
RDNT's Quick Ratio is ranked higher than
61% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. RDNT: 1.50 )
RDNT' s 10-Year Quick Ratio Range
Min: 0.15   Max: 1.72
Current: 1.5

0.15
1.72

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 3.31
RDNT's Price/Median PS Value is ranked higher than
59% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. RDNT: 3.31 )
RDNT' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 5.67
Current: 3.31

0.38
5.67
Earnings Yield (Greenblatt) 5.10
RDNT's Earnings Yield (Greenblatt) is ranked higher than
87% of the 253 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. RDNT: 5.10 )
RDNT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.7   Max: 8.8
Current: 5.1

2.7
8.8
Forward Rate of Return (Yacktman) -1.18
RDNT's Forward Rate of Return (Yacktman) is ranked higher than
58% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.29 vs. RDNT: -1.18 )
RDNT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -5.9   Max: 100.8
Current: -1.18

-5.9
100.8

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:PQIA.Germany,
RadNet Inc is incorporated in Delaware and has been in business since 1985. The Company provides freestanding, fixed-site outpatient diagnostic imaging services in the United States based on number of locations and annual imaging revenue. At December 31, 2012, it operated directly or indirectly through joint ventures, 250 centers located in California, Maryland, Florida, Delaware, New Jersey, Rhode Island and New York. Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. Diagnostic imaging involves the use of non-invasive procedures to generate representations of internal anatomy and function that can be recorded on film or digitized for display on a video monitor. Diagnostic imaging procedures facilitate the early diagnosis and treatment of diseases and disorders and may reduce unnecessary invasive procedures, often minimizing the cost and amount of care for patients. Diagnostic imaging procedures include MRI, CT, PET, nuclear medicine, ultrasound, mammography, X-ray and fluoroscopy. While X-ray remains the commonly performed diagnostic imaging procedure, the growing and higher margin procedures are MRI, CT and PET. The rapid growth in PET scans is attributable to the increasing recognition of the efficacy of PET scans in the diagnosis and monitoring of cancer. The number of MRI and CT scans performed annual in the United States continues to grow due to their wider acceptance by physicians and payors, an increasing number of applications for their use and a general increase in demand due to the aging population. The Companys sales and marketing team employs a multi-pronged approach to marketing, including physician, payor and sports marketing programs. The market for diagnostic imaging services is highly competitive. The Company competes locally with groups of radiologists, established hospitals, clinics and other independent organizations that own and operate imaging equipment. Its competitors include Alliance Healthcare Services, Inc., Diagnostic Imaging Group and several smaller regional competitors.
» More Articles for RDNT

Headlines

Articles On GuruFocus.com
Doral Financial Corp (DRL) Skyrockets with Unusual Market Activity, RadNet Inc (RDNT) Soars on Resul May 12 2014 
Weekly 3-Year Lows Highlight: FWM, FST, LAND, RDNT Jan 13 2014 
research Jun 12 2011 
research Jun 12 2011 
RadNet Inc. Reports Operating Results (10-K) Mar 11 2011 
RadNet Inc. Reports Operating Results (10-Q) Aug 09 2010 
RadNet Inc. (RDNT) Executive VP and CFO Mark Stolper sells 22,200 Shares Sep 22 2009 
RadNet Inc. (RDNT) Executive VP and CFO Mark Stolper sells 77,800 Shares Sep 21 2009 
RadNet Inc. (RDNT) Executive VP and CFO Mark Stolper sells 69,215 Shares Sep 21 2009 
RadNet Inc. (RDNT) Executive VP and CFO Mark Stolper sells 30,785 Shares Sep 18 2009 

More From Other Websites
RadNet (RDNT): Strong Industry, Solid Earnings Estimate Revisions Dec 09 2014
Elite Imaging Selects Comprehensive eRAD Platform Dec 01 2014
Reno Diagnostic Centers Implement eRAD RIS and RADAR for Efficiency Gains Nov 28 2014
Great Lakes Orthopedics and Sports Medicine Scales With eRAD PACS Nov 25 2014
Midwest Advanced Radiology Center Implements Full eRAD Platform Nov 21 2014
RADNET, INC. Financials Nov 18 2014
All Med Goes Live on eRAD PACS Nov 18 2014
eRAD Announces 12 New Customers for the 3rd Quarter of 2014 and YTD Implementations Not Previously... Nov 14 2014
10-Q for RadNet, Inc. Nov 13 2014
10-Q for RadNet, Inc. Nov 12 2014
RADNET, INC. Files SEC form 10-Q, Quarterly Report Nov 10 2014
RadNet and Kennedy Health System Announce the Start of their Diagnostic Imaging Joint Venture and... Nov 10 2014
RADNET, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 07 2014
The Jackson Clinic Purchases Complete eRAD Platform Nov 06 2014
Q3 2014 RadNet Inc Earnings Release - Before Market Open Nov 06 2014
RadNet beats 3Q profit forecasts Nov 06 2014
RadNet beats 3Q profit forecasts Nov 06 2014
RadNet Reports Record Third Quarter Financial Results and Adjusts Upwards 2014 Guidance Ranges for... Nov 06 2014
eRAD PACS and Mammography Module Deployed at Diagnostic Imaging of Salem Nov 03 2014
RadNet, Inc. Announces Date of Its Third Quarter 2014 Financial Results Conference Call Oct 24 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK